At the news
? BULLISHIMPACT 4/10 PRESS-RELEASE filed Aug 18, 2026 at 08:30 ET
Pliant Therapeutics announced FDA Fast Track designation for PLN-101095, an oral dual integrin inhibitor for ICI-refractory solid tumors. The designation provides regulatory benefits (rolling NDA, priority review eligibility) but is a procedural milestone, not a clinical data readout.
- FDA Fast Track designation granted for PLN-101095 in combination with pembrolizumab for ICI-refractory solid tumors
- PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins
- Currently being evaluated in Phase 1a/1b FORTIFY trial (NCT06270706) with data expected in 2027
- Fast Track benefits include frequent FDA meetings, rolling NDA submission, and priority review eligibility
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access